Katrine DiBona

Obesity is a global pandemic and is affecting children more than ever before. It is crucial to recognize the profound impact of childhood health on adult well-being. Research consistently shows that healthy children have a significantly greater likelihood of becoming healthy adults. The habits and behaviors established in early life often carry forward, shaping long-term health outcomes. Novo Nordisk is ready to be part of the solution by pioneering an initiative aimed at preventing childhood obesity in disadvantaged urban communities. We will invest 33 million euro over three years into investigating interventions aiming to increase physical activity and healthy eating among children across six cities. Investing in initiatives that support childhood health isn't just about the present; it's about securing a healthier and more resilient future. We need continuous dialogue between all societal actors and partners, and strong political leadership and action to shape a healthy future. 

30

How do we make multi-stakeholder and cross-sector collaborations in healthcare sustainable? 💡   This topic was discussed at today’s international Tour de Health'24 conference, where I was privileged to be part of sharing the learnings from Lighthouse Life Science in Denmark. “Are public-private strategic partnerships in Life Science sustainable?”, Maria Kristiansen discussed during her keynote followed by Diana Arsovic, who introduced the Danish public-private partnership Lighthouse Life Science to address chronic diseases. The panel discussed the learnings and potential of the Lighthouse Life Science to catalyse innovative and equitable action on healthy weight and mental health while simultaneously drive economic growth. Great knowledge sharing and networking between high-level governmental, non-governmental and other healthcare stakeholders from Denmark and the 13 Danish health diplomacy countries 🌎    Thank you to all participants, international delegates, and speakers for contributing to dialogue and knowledge exchange 🤝   Healthcare Denmark is hosting Tour de Health’24 in close collaboration with Danish Ministry of Foreign Affairs, Indenrigs- og Sundhedsministeriet and Ministry of Industry, Business and Financial Affairs. Tour de Health’24 is co-sponsored by Københavns Universitet - University of Copenhagen, Danish Industry, Dansk Erhverv, Novo Nordisk, and Lundbeck.   #TourdeHealth | #multistakeholdercollaboration | #partnershipsinhealth

144

1 Kommentar

📢 no outer change will happen without inner change first, together 🤝 🚀 IDG Summit 2024 to inspire and support your growth in community, online October 16-17 👇 to register! 💡 in what ways are you nurturing your personal growth? 💡 how making development a team sport is helpful and transformational? #IDG #InnerDevelopmentGoals #leadership #growth #transformation #impact

6

The health tech sector is flourishing, particularly in Denmark, where investments in startups surpassed €140 million in 2023. However, many companies encounter major hurdles in securing regulatory approvals in Europe, where the certification process can extend up to 18 months, compared to just 6-8 months in the U.S. These delays can stifle innovation and impact the timely delivery of cutting-edge health solutions to patients who need them most. Health Tech Pathways aims to change this. This new AI-powered platform will be developed by and anchored at Health Tech Hub Copenhagen, which supports health tech startups and the ecosystem to drive digital technology solutions for better health and patient care. Health Tech Pathways will offer bespoke regulatory support, with the goal of substantially reducing approval times and associated costs for Nordic startups. The platform will offer a suite of tools, including regulatory learning spaces, approval support, community forums, and AI-driven assistance. These resources aim to make the complex regulatory landscape easier to understand and to simplify the process of bringing health tech innovations to market. A special thank you to Signe Daugbjerg, PhD for her excellent work on this initiative.

145

10 Kommentarer

This week I have had the pleasure of returning to Stockholm, a beautiful city in which I had the good fortune to live for one year in 2002-03 shortly after the Astra and Zeneca merger. I met up with Jens Lingberg, CEO at Medivir. Jens and I were previous colleagues working in the lung cancer space at AZ. We enjoyed a good general catch up on the state of the world but in particular were able to marvel at the tremendous strides that have been made in increasing survival rales in cancer, particularly in NSCLC since those early years of the new millenium when we were working together. Our then pilot global team of Shanghai/Osaka/Europe/US based colleagues worked together seamlessly engaging with investigators and regulators alike to drive success, representing a model for the importance of collaborating globally to fight disease which knows no borders as we painfully saw through Covid. It was also fascinating to hear about the vibrancy in the Swedish Biotech space and discuss some of the similarities and differences, particularly in access to funding over the last few years with China. Jens’s team is now working on an Hepatocellular carcinoma program and it was really encouraging to see how Medivir has involved East and West to drive this program forward in another tumour type where we are beginning to see significant progress in extending life expectancy. Drug development is a long, challenging, and costly endeavour. It needs a wide variety of expertise and demands insights from multiple diverse sources to be successful globally. If you haven’t included China or Asia generally in your program, I encourage you to take a step back and have a re-think. 60% of the world’s population resides here. If its because you’re not sure how to or you are concerned about the perceived risks, please drop me a line [email protected] and I would be happy to discuss and potentially collaborate on a way foreward. #mycompany #Astrazeneca #Medivir #DrugDevelopment #China #Lungcancer #Hepatocellularcarcinoma

84

8 Kommentarer

Yesterday I led several discussions on #PrecisionOncology at Nordic Precision Medicine Forum @MarinaTower Stockholm, Sweden. Precision oncology enables tailored prevention, diagnosis, treatment and follow-up based on the individual patient's uniqueness which includes the genetic profile, increased knowledge about the protein and specific patterns of biomarkers. These signatures allow them to divide cancer categories into far more precise types and subtypes. Individualized Treatment will be possible thanks to precision oncology. When doctors tailor treatments based sometimes on the DNA signature of an individual patient’s tumour, by analysing both tumour and blood samples, they can make informed decisions about the most effective therapies. As treatments become more effective, or precise, both for the patient and from a socio-economical point of view, it can reduce unnecessary suffering for patients with improved outcome. Traditionally, cancers have been classified based on the type of tissue or body part where they originate (like lung, brain, breast, or colon). However, now radical shift is underway. Eminent participants were: Henrik Gronberg, Professor, Senior physician, Cancer Researcher of the Year, the Swedish Cancer Society, 2022, Karolinska Institutet held a lecture on "ProBio, An outcome-adaptive and randomized multi-arm biomarkerdriven study with metastatic prostate cancer" Helena Ullgren, Specialist Nurse Oncology and palliative care, Karolinska Institut presented on "Cancer nursing in the era of precision medicine. Margareta Haag, Chairperson, Network Against Cancer & Nasim Bergman Farrokhnia, Senior Industry Advisor, Healthcare Executive, Global Healthcare and Life Science Team, Microsoft focused on "How to measure what we want to know and know what we want to measure from a patient's perspective". We finalized the morning discussing how we can achieve a more #patientcentric precision oncology in Sweden and the Nordics. I was representing #AllCan Sweden together with Margareta and Nasim. Important to understand how various actors are shaping the new landscape of Health care‼️ Thankful for my eminent participants and the excellent job they are all doing to pave way to better health and modernizing health care. Last but not least, saving lives ❤️ #BMSSweden #Cancer #precisiononcology #precisionmedicine #patient #research #innovation

77

4 Kommentarer

On Friday, the Danish🇩🇰 government launched a new national life science strategy.🧬 The strategy, I dare say, is the most ambitious and comprehensive that Europe has seen in the life science area. Ambitions are thought broadly along the entire ecosystem from better conditions for research and health data - to biotech, investments and production – and for patient access to innovation including new medicine. As Novo Nordisk CEO Lars Fruergaard Jørgensen emphasized at the launch event of the new strategi – this is a strategy which EU should be inspired by when it comes to setting up ambitious and content of the up-coming new EU life science strategi🇪🇺. The DK Life science strategy takes an important step for both the life science industry and the Danish healthcare system with a clear ambition that Denmark should be a leader in the use of innovative, effective and sustainable healthcare solutions and medicines in the healthcare system. This will not only improve citizens' health, but also future-proof the healthcare system - and facilitate Denmark as a leading country for attracting new innovation and investment. At the same time, the strategy sets measurable ambitions and efforts to increase clinical research, production and foreign investments in life science in Denmark before 2030. The strategy continues to build upon collaboration as a strength under the auspices of the Danish Life Science Council and to anchor political coordination across the ministerial areas of responsibility with the existing life science units in the ministries. The Danish Government is already strongly engaged in the European agenda on how to improve conditions for life science innovation and competitiveness in European. The political commitment to take leadership on this key agenda is confirmed in our new national strategi. From Lif - Lægemiddelindustriforeningen “s side, we are very satisfied that Denmark is taking the lead in ensuring that the EU also develops an ambitious political strategy for life science, which should strengthen Europe's competitiveness, robustness and innovative power in the life science. This to be a key priority during the Danish EU Presidency on second half of 2025. Lif are looking forward to continuing our dialogue with Danish Government and politicians on the up-coming EU Life science Strategy. And to share coordination and experiences with our colleagues in EFPIA - European Federation of Pharmaceutical Industries and Associations and our “sister associations” across Europe.

36

1 Kommentar

Yesterday, Roche Danmark together with Danish Chamber of Commerce (Dansk Erhverv) co-hosted the event "Exploring European Life Science Competitiveness," bringing all of Roche’s General Managers in Europe together with key external stakeholders from Denmark to discuss how we can strengthen and maintain Europe's #competitiveness in the life science sector. The Danish Ministry of Business and Lif - Lægemiddelindustriforeningen each shared learnings and insights into Denmark's efforts to become a global leading life science nation and also how they prepare for the upcoming Danish EU presidency. We also had the opportunity to engage in fruitful discussions about the future of public private collaboration between industry and the healthcare sector to address capacity challenges and create societal value. A few key takeaways: → The life sciences sector is a crucial strategic asset for Europe, delivering innovations vital for the health and benefit of EU citizens and societies. However, we need to address challenges around access to new innovation and attracting R&D. Europe must become more attractive for investments as other global regions. → Unlocking the full potential of tomorrow’s resilient healthcare system requires prioritizing long-term value and impact from innovations, with data-driven decision-making as the key. Translating new knowledge and data into actionable strategies is essential for advancing our healthcare systems. Thanks to all participants for a great afternoon. #Roche #EU #Draghi #dklifescience #lifescience #pharma EFPIA - European Federation of Pharmaceutical Industries and Associations WifOR Institute

87

2 Kommentarer

If ONLY we knew how dietary behaviour will develop in the future ...  😶   ... wait a minute, maybe we can realistically model what likely happens, and which action package X might lead to a social tipping point of Y?    A new project funded by Novo Nordisk Foundation will study future transitions and tipping points in consumer-citizen food behaviour in Denmark. It does so by using existing behaviour insights to build a realistic model of how individuals act within the current food environment, and then testing what happens when this market and policy environment changes.    The outcome of the collaborative project are recommendations of how policy instruments, marketing measures, consumer-oriented innovations, and social dynamics can be combined to trigger societal tipping points. The project thus contributes to accelerating the transition by identifying effective combinations of key policy instruments and measures that can be implemented by market actors.    Partners of the collaborative projects at MAPP Centre are Copenhagen Business School Democracy x and international collaborators are ETH Zürich and Stockholm Resilience Centre  Funded by Novo Nordisk Foundation  Meike Janssen Arthur Hjorth Rune Baastrup Rasmus Mikkelsen Lukas Fesenfeld Rachel Mazac, Ph.D. Janus Porsild Hansen Lars Frederiksen   Find more here: https://lnkd.in/gXB-7yQ8    MAPP is an interdisciplinary research centre at Aarhus University conducting highest quality social science in the food system that results in relevant societal impact. 

24

1 Kommentar

How can the Danish healthcare make the needed green transition? lots of good perspectives from Sofie J. A. Helm Pedersen , Jakob Bjerg Larsen , Christof Bischoff and Frederik Dam van Deurs I was especially pleased to hear the focus on care pathways and patient journeys. we can't solve the green transition only focusing in the current silos product by product

7

CSRD (Corporate Sustainability Reporting Directive) has arrived. And that’s a good thing! For too long, ESG reporting has been a mixed bag of cherry-picking, marketing exercises, and at times, confusing information 🤷‍♀️ When talking sustainability transparency is key. This is exactly what the new CSRD directive is pushing for when it urges companies to deliver more clear, comparable, and precise data. Is CSRD perfect? No. The directive comes with challenges, but the direction is right ✅   I have given my perspectives in an op-ed by the media Altinget (Danish only). Link here 👇 https://lnkd.in/dMJkShKQ

347

7 Kommentarer

🌟 Great news for accessibility and healthcare in the Nordics! 🌟 The Nordic countries are collaborating on standardized packaging for medicines, aiming to enhance availability and reduce complexity. This initiative allows pharmaceuticals to be marketed across Nordic nations under a unified packaging system (English/English pack). The result? Faster access to essential medications, improved efficiency for manufacturers, and better patient experiences. By simplifying regulatory requirements and aligning processes, this step ensures patients in smaller markets like Norway, Sweden, Denmark, Finland, and Iceland get the medications they need more reliably. It's a win for healthcare, sustainability, and Nordic cooperation! #Only a few in this pilot but hoping for more, check if your product is eligible. And for producers in Europe of those substances not yet in the Nordics, this is your way in! Maja Graf I hope you will help them to get in contact! Fantastic work; DMP and Nordic collegues: Dag Jordbru @karl høgstrøm @margret heidarsdottir Katarina Lönnquist Cecilia Ulleryd and more. #NordicInnovation #HealthcareAccessibility #DMP

63

4 Kommentarer

Teenagers often outgrow their clothes – shirts don’t fit, jeans are too short. The same goes for websites. Last year, Science Hub supported around 35 congresses where Novo Nordisk presented its latest science and scientific publications. And in 2024, this has grown to more than 50 congress activities and an increasing number of users. That’s why we recently launched a new online experience for Science Hub that improves the user experience, both visually and in terms of performance. Simply to make it easier for healthcare professionals to find the congress materials, scientific publications and independent medical education relevant to them – all in one place. Explore the new Science Hub+ here: https://lnkd.in/dvvGXKwQ A big thank you to all of the good colleagues who have been involved in the project, as well as our UX, design and technical partners, for reaching this great milestone. Credits: Design: Manyone Implementation: Netcompany PS: If you’re trying to access the link from Denmark, you may be blocked. This is simply because scientific exchange is restricted to healthcare professionals only – so it’s us, not you. If you work for Novo Nordisk and you’re also blocked, try accessing via the company VPN.

65

6 Kommentarer

♻️ LOOP Forum is back ♻️ Here are some conference participation reflections nobody asked for: ☕️ I always try to make time to just engage… Wander into unexpected conversations, ask a curious question of someone from a completely different sector or just sit down for a while to get a feel for the flow. This is co-creation in action. 🌿 I had a lot of fun exploring how the setting elevated the content – from pre-ordered lunch (reducing food waste) and reusable cups (eliminating branded, single-use cups) to hosting a circularity conference in a repurposed locomotive workshop brings the story to life. 🏃‍♀️ I aim to be impressed – and then go do! For me, that means trying to return to regular work with at least a couple of concrete actions I’d like to set in motion based on what I’ve learned. What are your best conference tips (besides snack scouting)? 👐

24

It's truly inspiring to see Denmark taking a significant step towards creating its own internationally leading innovation district for life science and quantum technology, akin to Boston's Kendall Square. Here, companies and researchers will be able to work side by side, which will create a wealth of opportunities to attract the necessary resources, including capital and competencies, to Denmark. The collaborative effort between the Danish government and the Municipality of Copenhagen to develop the area around the Københavns Universitet - University of Copenhagen North Campus, including Copenhagen Science City, is a testament to our country's commitment to innovation. I would like to extend my sincere gratitude to all involved for their leadership and support for this initiative. I believe this world-leading hub has the potential to supercharge innovation in Denmark, and will significantly strengthen the ability of Danish companies to translate research into commercial application for the benefit of people and the planet. The innovation ecosystem in Denmark is already robust. Yet, there’s room for even greater impact. This proposed innovation district could be the catalyst we need to unlock that untapped potential. Just like Kendall Square, this precinct could become the springboard for transformative innovations that benefit both human and planetary health!

262

12 Kommentarer

Climate change poses a critical threat to biodiversity and agricultural productivity. By learning from the past, we can foster more sustainable food systems. This is why the Novo Nordisk Foundation, in partnership with Wellcome Trust, has committed up to DKK 585 million to the Ancient Environmental Genomics Initiative for Sustainability (AEGIS). This pioneering project, led by evolutionary geneticist Professor Eske Willerslev, will leverage environmental DNA (eDNA) to explore ancient ecosystems and species adaptations to help develop climate-resilient food systems.   For further information, please read the press release

98

1 Kommentar

2024 will indeed be an exciting life science year! With a new Danish life science strategy just around the corner and a renewed Swedish life science strategy materializing before the end of the year, Denmark and Sweden as the major life science nations, we are in the EU, will be fueling further growth and attractive frame work conditions for continuous research, development, public-private collaboration and internationalization of the life science sector. As the cross-border Swedish-Danish life science cluster Medicon Valley Alliance is, we are hoping both strategies also will embrace the opportunities that lies in collaborating cross-border between our two countries that have so much in common within the challenges and opportunities in our ambitions about the life science industry and healthcare system. Joint clinical trials, utilizing the synergies in development of the new medicines like the ATPMs, exploring the potential of our amazing health care data, becoming a front runner with Women's Health - all examples of where we would be much stronger and attractive together than on our own. A big thank you for Jeanette Edblad for taking time to discuss the potential and how Medicon Valley Alliance as a Swedish-Danish life science cluster organization can support the future renewed Swedish life science strategy and help strengthen the Swedish (and Danish) ambitions of becoming leading life science nations. Morten Bødskov Ebba Busch Jeanette Edblad Maria Björkqvist Ebba Fåhraeus Stefan Jovinge Anna Ax

139

1 Kommentar

Learning should be a life long pursuit. I'm very excited to be taking Läkemedelakademins (Swedish Pharmaceutical Scienced Academy) program for life science professionals on clinical drug development & GCP (good clinical practices, ICH E6 GCP). With a background in HEOR (health economics), I'm further enhancing my knowledge of the management of the medicinal product life cycle. Next up is the LIF examen/certification with modules in anatomy, pharmacology and pathology. #heor #marketaccess #clincialtrials #drugsafety #lifexamen

10

1 Kommentar

Preparations for EU joint HTA are being stepped up by the Swedish government. “We want to ensure that Swedish conditions and perspectives have an impact internationally, and that the documents produced at EU level are useful in Sweden,” says Health Minister Acko Ankarberg Johansson.   To that end, the Tandvårds- och läkemedelsförmånsverket (TLV; Dental and Pharmaceutical Benefits Agency), the Läkemedelsverket (Swedish Medicines Agency) and the Statens beredning för medicinsk och social utvärdering (SBU; Swedish Agency for Medical and Social Evaluation) will form a new collaborative structure for HTA within the country’s healthcare system. The government will give each organisation a budget of SEK 2 million (€175,000) to support this initiative. In its 2023 annual report, TLV had remarked that “a large part of the past year has been devoted to participating in the preparatory work at EU level, not least to ensure that the upcoming system will be as functional as possible. Unfortunately, TLV has not received resources for this, but it is currently crowding out other urgent work at the authority, which is not reasonable in the long run.”   According to TLV, a central part of the national preparatory work is “to adapt the national case handling processes to the processes at EU level. This is done, among other things, by mapping current processes, analysing the need for changes based on the requirements of the [HTA] Regulation, and developing proposals for implementing this change.”   TLV notes that, “when the Regulation begins to be applied, new work steps will also be required. An example of this is that, at an early stage, TLV quickly needs to produce national review scopes (so-called PICOs) before the evaluations at EU level.” PICO preparation “will be done for all products that go through EMA's processes, which is significantly more products than the authority evaluates today. Internal work is under way to develop a proposal for organisation and working methods that will enable this. Among other things, there will be a need for statements from clinical experts, which requires a developed collaboration with the regions. TLV and SBU, as members of the working group for joint clinical reviews, … will have to cooperate in the development of the Swedish review scope.”   The three agencies involved in the new Swedish HTA collaborative structure will be required to submit a written report on the assignment to the Ministry of Social Affairs by 13th December 2024 at the latest. #Sweden #EU #jointHTA #JCA

153